Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Market Reports
Why potency assays are a crucial consideration for CGT manufacturers
Potency assays can enhance the efficiency of cell and gene therapy development and commercialisation while also bringing down costs
How iPSCs can bridge the translational gap in neuroscience
Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
Clinical trials: current insights and future perspectives
To keep up with the ever-evolving landscape of clinical trials, companies must conform to regulations and consider how to make the study process patient-centric
Recombinant versus synthetic peptide synthesis: the perks and drawbacks
Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
ACHEMA 2024 champions a competitive pharmaceutical industry
More than 2800 exhibitors from 56 nations — as well as 106,001 attendees from 141 countries — gathered in Frankfurt for ACHEMA 2024 to showcase the latest equipment and processes for the pharmaceutical industry
How predictive and preventive maintenance can optimise your pharmaceutical manufacturing line
With a tailored approach to maintenance, manufacturers can extend their system’s lifetime and anticipate time-consuming breakdowns before they happen
Factors driving the expansion of the multiple myeloma drug market
The multiple myeloma market has seen a range of immune-targeting therapeutics gain accelerated approval from the US FDA … and sales are predicted to skyrocket in the coming years
Biosecurity threats and business as usual
A new version of a United States congressional bill (the Biosecure Act) that restricts US companies from doing business with certain Chinese biotechnology organisations, including WuXi AppTec and WuXi Biologics, gives American companies until 2032 to terminate their associations with these firms and find new partners
Annex 1-compliant freeze drying: a technology supplier’s perspective
Jessica Wagner, Validation Engineer at GEA, tells Dr Kevin Robinson how the company has embraced the updated version of Annex 1 and implemented the new changes. Key objectives were to remain compliant and demonstrate to their customers — both current and future — how the amends would be incorporated into ongoing or upcoming projects
Optimising labelling with robotics for improved accuracy and efficiency
Robotics can significantly enhance the labelling process during pharmaceutical packaging by increasing accuracy whilst reducing costs and labour
How efficient compressed air delivery can save you money
Investing in optimal filtration systems for compressed air delivery is crucial in saving money and reducing energy usage
How to proactively address EU HTAR implementation challenges before 2025
Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
Adding more to the cell and gene therapy playbook
With notable advances in various forms of administration, including making the use of viral vectors safer, non-viral delivery with lipid nanoparticles and the growing application of electroporation, Dr Kevin Robinson (KSR) recently caught up with Jason Potter (JP), Director of Cell Biology R&D at Thermo Fisher Scientific, to learn more about how the company is helping the pharmaceutical industry to develop cell and gene therapies
What to consider for successful GMP Annex 1 implementation
In advance of her presentation at Manufacturing Chemist Live, Dr Nicole Hunter (NH), Head of Global Regulatory and Validation Services at Watson-Marlow Fluid Technology Solutions, and colleague Claire Hutchison (CH), Life Science Specialist, provide their insights on the updates to the European Commission’s Good Manufacturing Practices (GMP) Annex 1 and the role of single-use systems
Highly potent formulation development in oncology
Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary pressure to the development process — some of which are avoidable. Louise Carpenter from PCI Pharma Services discusses
Going beyond the guidance: getting business benefit from change management
Change management offers a broad, system-wide perspective that includes the oversight and management of all changes and the change process. Michelle Anastasi of PharmaLex explores what good change management looks like and who should be involved
QMM: a natural development of pharmaceutical regulation?
During the pandemic, we saw a rapid evolution of inspection approaches that showed how the sector — and indeed the regulators — can adapt to new operational models
SCHOTT Pharma reveals strong financial performance in fiscal year 2022
In a record year of growth, sales increased by 27% to EUR 821 million and EBITDA by 33% to EUR 219 million on a preliminary basis
Made in Switzerland: blockchain enabled healthcare
Interoperable blockchain-enabled solutions could eliminate waste, enhance security and privacy, build trust and, ultimately, benefit patients and the entire pharmaceutical value chain, say the founders of PharmaLedger. Dr Kevin Robinson dialled in to find out more
Brenntag signs multi-year partnership with Workday Human Capital
The chosen Workday HCM solution will be tailored and implemented in the course of 2023 to meet the needs of Brenntag
From food to pharma: antioxidant scavengers as a viable strategy to mitigate nitrosamines in drugs
Stakeholders throughout the pharmaceutical value chain have had to deal with the recall of nitrosamine-containing medications, loss of revenue and, in some cases, reputational damage. Meanwhile, regulatory authorities have put stringent measures in motion to protect patients from potentially harmful medications, putting reformulation at the forefront of drug manufacturers’ minds, reports Anne-Cecile Bayne, Global Science and Innovation Lead, Pharma and Medical Nutrition at DSM
FUJIFILM launches viral vector feed designed to increase yields
FUJIFILM Irvine Scientific has launched its BalanCD HEK293 Viral Feed designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines
Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment
Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology
Host cell protein analysis: strategies to improve sensitivity and reproducibility
Given that the US FDA approved 25 new cellular and gene therapy products in 2022, gene-based vaccines and therapeutics have now entered the mainstream pharmaceutical industry. However, the rising interest in gene-based strategies puts pressure on manufacturers to demonstrate optimum efficacy and safety
Previous
1
(current)
2
3
4
5
6
7
8
9
Next
Trending Articles
How to avoid sticking and picking in the tableting industry
John Norman and Kevin Queensen of Natoli Engineering explain
Addressing glass particulates in injectable drug formulations
Glass particles are a frequent contaminant risk when producing injectable drugs on high speed filling lines. Glassmaker Corning has studied the root causes and engineered a new glass product for use on existing equipment that significantly reduces that risk
Recombinant versus synthetic peptide synthesis: the perks and drawbacks
Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
Peak identification by LC/MS: Automation versus analyst
High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
How iPSCs can bridge the translational gap in neuroscience
Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
Upcoming event
CPhI Middle East
10–12 December 2024 | Conference | Riyadh, Saudi Arabia
See all